An Exercise Prescription to Slow the Progression of Parkinson’s Disease
Objective: To evaluate the efficacy of a 12-month, home-based, high-intensity aerobic exercise intervention in slowing the progression of Parkinson’s disease (PD) using rate-focused cycling. Background:…Apathy and Risk of Parkinson’s Disease: A Population-Based Cohort Study
Objective: This study investigated the association between apathy and the risk of incident Parkinson's disease (PD) in community-dwelling adults. Background: Apathy is a core neuropsychiatric…Effect of Exenatide on disease progression in early Parkinson’s disease–a randomized, placebo controlled, single-center trial in Sweden
Objective: To identify biological mechanisms that mediate Exenatide's effect in the brain of patients with early Parkinson’s disease(PD). Background: Tracking PD progression remains a major challenge due to…The Bjorn Moller Research Repository: A Resource for Movement Disorders Research
Objective: To build a repository of longitudinally collected biological samples and clinical, demographic, and lifestyle data from individuals with Parkinson’s disease (PD) and other movement…Methodological considerations supporting a time-to-event primary endpoint in the PADOVA study in early-stage Parkinson’s disease participants on stable symptomatic treatment
Objective: To provide the methodological rationale for using a time-to-event (TTE) primary endpoint in the PADOVA study. Background: The use of symptomatic medications represents a…Mathematical and Computational Modeling Prototype to Understand the Evolution of Parkinson’s disease using Four Differential Equations
Objective: Apply four differential equations to generate projections considering the effect of dopamine on Parkinson’s disease progression, leading to the development of an initial prototype…Quality of Life Improvements in Parkinson’s Disease for Those Treated with Photobiomodulation Plus Exercise: A Sham-Controlled Study
Objective: To assess whether exercise alone, or exercise combined with photobiomodulation (PBM) can improve the health-related quality of life (QoL) for people with Parkinson’s disease…CAP-003, a CNS-targeted IV-delivered AAV Gene Therapy Developed for Patients with Parkinson’s Disease associated with GBA1 Mutations
Objective: CAP-003 is a next-generation gene therapy candidate, comprising a novel brain-tropic capsid paired with hGBA1 cargo, that was developed for administration as a single…The 201 Trial in Untreated Parkinson’s Disease
Objective: To evalute the safety, tolerability, clinical benefit and protein pathology status following risvodetinib (IkT-148009) treatment in participants with untreated Parkinson's disease. Background: RIsvodetinib is…the role of the “unfolded protein response” and the perk pathway in parkinson’s disease: study of genetic polymorphisms
Objective: To study a possible association between polymorphisms of the genes coding for proteins involved in the UPR and the development of PD or PD…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 19
- Next Page »